dolutegravir
State of the ART: HIV Management in 2025
Earlier initiation of ART and better medication options have resulted in a narrowing in the mortality gap between ...
JULY 3, 2025
For Advanced HIV, 2-Drug Dovato Regimen as Effective as 3 Drugs
The two-drug regimen of dolutegravir-lamivudine achieves comparable efficacy to three-drug therapy regimens in ...
FEBRUARY 28, 2025
Study Verifies Real-World Efficacy and Tolerability of Dolutegravir 2-Drug Regimens
Real-world data from HIV patients in the United States show strong efficacy and tolerability of dolutegravir-based ...
JUNE 13, 2024
FDA Grants New Indication for Dovato to Treat Adolescents 12 and Older
The FDA granted a new indication for Dovato to treat HIV-1 infection in adolescents 12 years of age and older and ...
APRIL 8, 2024
New Blister Packs Available for Dovato
ViiV Healthcare announced that dolutegravir-lamivudine (DTG/3TC; Dovato) is now available in a blister pack in the ...
FEBRUARY 5, 2024
For HIV, DTG-based ART Increases Probability of Maternal Viral Suppression at Delivery
Dolutegravir-based therapy during pregnancy suppressed viral loads at delivery.
SEPTEMBER 8, 2022
Dolutegravir-Based ART Is Superior to Standard Care in Adolescents
Results from a multicountry, phase 3 basket trial found that antiretroviral therapy (ART) based on dolutegravir ...
JUNE 28, 2022
New Studies Show Neural Tube Risk With Dolutegravir Lower Than Thought
WHO updated its global HIV treatment recommendations based on new data showing that even though dolutegravir during ...
JULY 24, 2019
The Forgotten Patient
At the beginning of the HIV epidemic in the United States, disparities in HIV incidence were clearly seen. ...
JUNE 11, 2019
FDA Approves Dovato—First 2-Drug Complete Regimen for HIV
Dovato is a single table regimen containingdolutegravir-lamivudine and is approved as a complete regimen for the ...
APRIL 8, 2019
Positive Initial Results From Twin GEMINI Studies Signal Hope for 2-Drug Strategy in HIV
There is reason for cautious optimism that HIV regimens can be simplified without sacrificing safety or efficacy, ...
SEPTEMBER 21, 2018
Dolutegravir Maintains Virologic Suppression in Multiple Trials
Dolutegravir-based regimens provide long-term suppression in HIV patients, according to presentations at the 22nd ...
JULY 26, 2018
